Skip to content
Screener

Organogenesis Holdings Inc. ORGO Total Operating Expenses

Total Operating Expenses at other companies

SANUWAVE Health, Inc. logo
SANUWAVE Health, Inc.SNWV
$7.7M+20.2%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$18.09M-2.5%
AngioDynamics logo
AngioDynamicsANGO
$56.97M+18.7%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$30.37M+5.3%
Sanara MedTech Inc. logo
Sanara MedTech Inc.SMTI
$24.38M+14.0%
TTR
Turn Therapeutics Inc.TTRX
$1.25M+224%

Other financials

Income statement

See full
Revenue$43.8M-56.7%
Gross profit$63.0M-22.5%
Operating income-$51.0M-305%
Net income-$96.3M-925%
EPS (diluted)-$0.77-670%

Balance sheet

See full
Cash & equivalents$46.1M-36.9%
Total debt$36.6M+19.2%
Total equity$148.3M-36.4%
Total assets$406.4M-11.9%

Cash flow

See full
Operating cash flow-$31.7M+3.7%
CapEx$1.1M-69.8%
Free cash flow-$32.8M+10.3%

Valuation

See full
Market cap$239.33M-59.1%
Enterprise value$229.8M-57.7%
P/S0.5×-0.8×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin-7.8%—
Net margin-18.4%-20.8pp
FCF margin6.9%—

Returns & leverage

See full
Return on equity-44.1%-48.0pp
Debt / equity0.2×+0.1×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Organogenesis Holdings Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Organogenesis Holdings Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338049
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Selling, general and administrative53,96573,810119,151146,319
Research and development18,29710,39533,45821,035
Fair value adjustment to assets held for sale(1,188)1,746(1,188)8,313
Total operating expenses94,747113,581200,866227,020
Loss from operations(50,992)(12,576)(119,883)(39,322)
Other income, net:
Interest income, net1386695181,630
Other income (expense), net(26)731275

Item 1. Unaudited Condensed Consolidated Financial Statements.

FAQ

What is Organogenesis Holdings Inc.'s total operating expenses?
Organogenesis Holdings Inc. (ORGO) reported total operating expenses of $94.75M in Q2 2026.
How has Organogenesis Holdings Inc.'s total operating expenses changed year-over-year?
Organogenesis Holdings Inc.'s total operating expenses decreased by 16.6% year-over-year, from $113.58M to $94.75M.
What is the long-term trend for Organogenesis Holdings Inc.'s total operating expenses?
Over 4 years (2021 to 2025), Organogenesis Holdings Inc.'s total operating expenses has grown at a 16.6% compound annual growth rate (CAGR), from $280.94M to $519.48M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Organogenesis Holdings Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude